Compare GF & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GF | ACHV |
|---|---|---|
| Founded | 1990 | N/A |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 172.0M |
| IPO Year | N/A | 2018 |
| Metric | GF | ACHV |
|---|---|---|
| Price | $11.48 | $3.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 46.3K | ★ 805.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.81 | $1.95 |
| 52 Week High | $12.82 | $6.03 |
| Indicator | GF | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 64.04 | 51.19 |
| Support Level | $11.34 | $2.69 |
| Resistance Level | $11.80 | $3.90 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | 0.18 | 0.10 |
| Stochastic Oscillator | 85.64 | 89.59 |
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.